This is because of understandable investor concerns about falling revenues as exclusivity on various drugs comes to an end.Specifically, AstraZeneca faces patent expiries between now and 2015 on drugs such as Seroquel and Nexium, and the loss of patent protection in the US in 2016 for its best-selling high cholesterol treatment drug, Crestor.On Wednesday, the company reaffirmed that it expects ann